By Leonid Schneider, on research integrity, biomedical ethics and academic publishing
EuroImmun is a German diagnostics biotech, founded by the most charming Professor Stöcker and recently sold to PerkinElmer. Elisabeth Bik checked some of company’s papers, many coauthored by Stöcker himself, and she raised questions. The company says this “testifies to a lack of knowledge of the matter”.
A dishonest cancer researcher. A dud cancer drug based on rigged lab data. A clinical trial in The Lancet. A greedy university which finds no misconduct. And a medical journal which tramples over patients.
Ashutosh Tiwari and his patron Tony Turner were found guilty of research misconduct by Linköping University. Turner is to be sacked as EiC of his Elsevier journal Biosensors and Bioelectronics, a paper he tried to correct there will be retracted. Meanwhile, Tiwari and his LiU colleague Mikael Syväjärvi started a new business: they offer heart surgeries in India.
Liverpool professor Patricia Murray continues investigating shady dealings of the regmed company Celixir, owned by struck-off dentist Ajan Reginald and Nobelist Sir Martin Evans
In 2018, the pharma giant Sanofi appointed with John Reed a new R&D head. Apparently Sanofi does not believe in PubPeer.
Get ready to meet Dr Richard Hill and his amazing jumping blots. Just don’t stare, or you’ll get hurt.
Patricia Murray uncovers the business secrets of the Nobelist Martin Evans and his partner Ajan Reginald. It seems the magic iMP cells used to treat patients in Greece were drawn from the blood of patients in Swansea, for the purpose of a secret PhD thesis. There is no serious science behind it, only serious investor money and a fraudulent patent.
The new ERC President Mauro Ferrari used to closely collaborate with two very controversial cancer researchers at MD Anderson in Texas: Anil Sood and Gabriel Lopez-Beerestein. Will that experience affect ERC’s already wanting stance on research integrity?
Sir Martin Evans, winner of Nobel prize 2007, founded in 2009 the stem cell start-up Celixir, together with a struck-off dentist Ajan Reginald. With the help of the British heart surgeon Stephen Westaby, they ran a very profitable clinical trial in Greece, which now moved into UK.
The trachea-transplanting company Videregen, based in Liverpool, got another £2 million grant from UK governmental agency Innovate UK, to advance their tracheal replacement technology.
For Better Science